Abstract
Objectives-To describe the abnormalities in CSF from HIV infected patients with acute lumbosacral polyradiculopathy (ALP) caused by cytomegalovirus (CMV) infection. Methods-Retrospective case notes and laboratory records were reviewed for 17 consecutive patients with CMV associated ALP admitted to specialist HIV/AIDS units at UCL Hospitals and Chelsea and Westminster Hospital. Results-Infection with CMV was confirmed by detection of CMV DNA by polymerase chain reaction amplification in 15 patients (all of whom were negative by culture), by culture in one patient, and by objective clinical response to anti-CMV treatment in one patient. Only nine patients had a CSF pleocytosis 28- 12 and myelography in two; one patient had both investigations) and four patients had electrodiagnostic studies of the legs.
In all patients CSF protein and glucose concentrations were determined and the presence or absence of CSF pleocytosis was noted. The By contrast with previously published reports only nine of the 17 patients in our study had a CSF pleocytosis; of these patients polymorphonuclear cells were the predominant cell in seven patients. These data suggest that if the presence of a polymorphonuclear leucocyte pleocytosis was used as a requirement for diagnosis of CMV associated acute lumbosacral polyradiculopathy in patients presenting with subacute onset of flaccid paraparesis then in about half, institution of specific anti-CMV treatment might be delayed pending the finding of CMV in CSF.
The data from our study contrast with those from a study of acute lumbosacral polyradiculopathy in 23 patients with AIDS by So and Olney.5 They reported that 14 patients had a pronounced pleocytosis with a preponderance of polymorphonuclear cells, mean count 756 cells/mm,3 range = 81-1230 cells/mm3; in eight of these patients CMV was isolated from CSF by culture. In nine other patients there was a low grade CSF pleocytosis, mean cell count = 13 cells/mm,3 range = 0-37 cells/ mm,3 consisting predominantly of monocytes; CMV was cultured from CSF in only one of this group of patients and two of these patients had lymphoma, identified by cytological examination of CSF, as the cause of their neurological presentation.5 It was reported that those patients with a monocyte predominant pleocytosis, who did not have lymphoma as a cause, had a slower clinical progression and a milder neurological deficit, and that spontaneous improvement without treatment was common.5 In our study eight patients had no pleocytosis and we were unable to show any correlation between the duration of symptoms or the severity of neurological deficit and the presence or absence or type of CSF pleocytosis. However, survival in those with a pleocytosis was worse than in those without. It is possible, even though negative culture of CMV from CSF does not exclude CMV infection, that some of the patients in the study by So and Olney who had a monocytic preponderant pleocytosis and no detectable CMV infection, did not in fact have CMV induced disease.
The reported CSF changes in response to treatment of acute polyradiculopathy with ganciclovir are varied. 6 In those who respond clinically to treatment there is often an associated reduction in the CSF pleocytosis. Of our patients only two were already receiving ganciclovir at the time of lumbar puncture, one as long term oral maintenance, the other intravenously. Both patients had a polymorphonuclear leucocyte pleocytosis. Thus use of anti-CMV therapy does not explain the varied CSF pleocytosis seen in our patients.
In our study 13 patients had moderate or pronounced increase in CSF protein; however two patients had normal or nearly normal CSF protein without a pleocytosis or depression of the CSF:plasma glucose ratio. Clearly there is a range of CSF inflammatory response seen in this group of patients which mirrors the range of severity of neuropathological damage induced by CMV.282432 Several studies have shown the low sensitivity of conventional viral culture of CSF for identification of CMV and the high sensitivity and specificity of CMV DNA detection by PCR amplification in HIV infected patients with CMV associated neuro- 7 11 12 2228 31 logical disease.
In one study of 164 consecutive HIV infected patients undergoing lumbar puncture 26 had confirmed CMV associated neurological disease (encephalitis in 12, mononeuritis multiplex in nine, and polyradiculopathy in five). CMV DNA was detected in CSF from 24 of these patients and in only four patients without CMV associated neurological disease giving a sensitivity of 92%, a specificity of 94%, and a negative predictive value of 97%.3' In another study 39 of 111 consecutive HIV infected patients had suspected CMV associated neurological disease; CMV DNA was detected in CSF of 24 of the 39 (62%) and in only eight of 72 patients with alternative diagnoses.'2 Whereas it is known that there is a high prevalence of latent CMV infection in HIV infected patients these studies confirm that expression of CMV and detection of viral DNA in the CSF is strongly associated with the presence of CMV associated neurological disease. Our study confirms that DNA detection is more sensitive than culture for virus detection from CSF in HIV infected patients with acute lumbosacral polyradiculopathy and suggests that this method should be used for diagnosis.
In conclusion, in this small study, we have shown that the CSF abnormalities occurring in patients with CMV associated acute lumbosacral polyradiculopathy are varied. "Classic" changes of a pleocytosis consisting predominantly of polymorphonuclear leucocytes are present in only half of the patients; some patients may have a normal CSF without increased protein or depression of the CSF:plasma glucose ratio. In view of these findings patients with advanced HIV disease presenting with subacute flaccid paraparesis should have the diagnosis of CMV infection made by identification of CMV DNA in CSF by PCR amplification and by exclusion of other opportunistic infections and lymphoma, in order that specific anti-CMV therapy may be instituted promptly.
